House Passes Bill that Seeks to Expand FDA’s Role in Rare Pediatric Disease Research

On December 1, the House of Representatives passed the bipartisan Mikaela Naylon Give Kids a Chance Act (H.R. 1262), which intends to increase access to innovative treatments for children by reauthorizing the FDA’s Rare Pediatric Disease (RPD) Priority Review Voucher (PRV) Program to incentivize the development of treatments for rare pediatric diseases and authorizing the FDA to direct companies to study a combination of cancer drugs and therapies in pediatric trials. This bill will need to be passed by the Senate.